Latest Listings And Ipos News

Prime Financial Group has reported robust FY25 results, doubling its revenue run rate and expanding its high-net-worth client base through strategic acquisitions. The company sets ambitious growth targets for FY26 and beyond, underpinned by technology investments and leadership enhancements.

CD Private Equity Fund III reported a $3.02 million net loss for the half-year ending September 2025, driven largely by foreign currency translation losses, yet maintained a 10 cent per unit distribution supported by portfolio realisations and cash management.

The Federal Court of Australia has approved the acquisition scheme for Lynch Group Holdings, paving the way for a cash payout to shareholders and imminent trading suspension.

Hexima Limited reveals plans to return capital to shareholders and restructure its board following the closure of its main clinical program and prolonged ASX trading suspension.

Kingsgate Consolidated Limited reported record quarterly gold and silver production at its Chatree Gold Mine, alongside strong cash growth and strategic project advances in its November 2025 AGM update.

Jindalee Lithium has successfully raised $1.5 million through an oversubscribed Share Purchase Plan, exceeding its $1 million target to fund the McDermitt Lithium Project and a US SPAC transaction.

Global Lithium Resources has lodged a prospectus for MB Gold's IPO, aiming to raise $6 million by spinning out its Marble Bar gold assets. This strategic move sharpens Global Lithium’s focus on its lithium projects while unlocking value from its gold holdings.

Pathkey.AI has secured A$2.5 million through a placement and launched a nearly A$1 million rights issue to fund expansion of its AI-driven TrialKey platform and pursue strategic acquisitions, alongside key board changes.

Aurora Energy Metals and Eagle Energy Metals have agreed to extend the option period for Eagle's acquisition of the Aurora Uranium Project to mid-2026, adjusting milestone timings due to US government shutdown delays impacting Eagle's Nasdaq listing.

Anteris Technologies Global Corp. has filed a Form S-1 registration statement with the SEC to enable resale of shares issued in a recent private placement, marking a key step in advancing its DurAVR transcatheter heart valve system and pivotal clinical trials.

Ironbark Capital reported an 8.4% portfolio return for FY25 and announced plans to rebrand and introduce quarterly dividends to address its persistent discount to net tangible assets.

Race Oncology has received a $2.8 million Australian R&D tax refund for FY2025, with further overseas R&D rebates expected, bolstering its clinical development of innovative cancer therapies.